-+ 0.00%
-+ 0.00%
-+ 0.00%

SONESITATUG VEDOTIN GRANTED PRIORITY REVIEW IN THE US FOR 2ND AND LATER-LINE TREATMENT OF PATIENTS WITH CLDN18.2-POSITIVE ADVANCED GASTRIC/GEJ CANCERS

Reuters·11/19/2026 12:00:01

Please log in to view news